Literature DB >> 11682263

Hypothalamic-pituitary-adrenal axis dysregulation in depersonalization disorder.

D Simeon1, O Guralnik, M Knutelska, E Hollander, J Schmeidler.   

Abstract

BACKGROUND: The purpose of this preliminary study was to investigate HPA axis function in dissociation.
METHODS: Nine subjects with DSM-IV depersonalization disorder (DPD), without lifetime Posttraumatic Stress Disorder (PTSD) or current major depression, were compared to nine healthy comparison (HC) subjects of comparable age and gender.
RESULTS: DPD subjects demonstrated significant hyposuppression to low-dose dexamethasone administration and significantly elevated morning plasma cortisol levels when covaried for depression scores, but no difference in 24-hour urinary cortisol excretion. Dissociation scores powerfully predicted suppression whereas depression scores did not contribute to the prediction.
CONCLUSIONS: Primary dissociative conditions, such as depersonalization disorder, may be associated with a pattern of HPA axis dysregulation that differs from PTSD and merits further study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682263     DOI: 10.1016/S0893-133X(01)00288-3

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  3 in total

Review 1.  Depersonalisation disorder: a contemporary overview.

Authors:  Daphne Simeon
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Hypothalamic-pituitary-adrenal axis function in dissociative disorders, post-traumatic stress disorder, and healthy volunteers.

Authors:  Daphne Simeon; Margaret Knutelska; Rachel Yehuda; Frank Putnam; James Schmeidler; Lisa M Smith
Journal:  Biol Psychiatry       Date:  2006-11-29       Impact factor: 13.382

3.  Multimodal assessment of emotional reactivity in borderline personality pathology: the moderating role of posttraumatic stress disorder symptoms.

Authors:  Katherine L Dixon-Gordon; Kim L Gratz; Matthew T Tull
Journal:  Compr Psychiatry       Date:  2013-02-01       Impact factor: 3.735

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.